Search - tctmd.com

Displaying 61 - 80 of 120

Sort: Relevancy | Date

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

News Daily News

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

Michael O'Riordan

March 11, 2020

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

News Daily News

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

March 02, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

February 24, 2020

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

News Daily News

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

November 01, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

October 18, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

September 12, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

March 17, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.